List view / Grid view
15 February 2016 | By Edinburgh Instruments
We are delighted to have accomplished installation of our top end fluorescence spectroscopy systems at the brand new Vidyasirimedhi Institute of Science and Technology (VISTEC) in Thailand...
12 February 2016 | By Victoria White
Heart UK has questioned why the NICE did not seek the expertise of lipidologists during its latest review of PCSK9 cholesterol-busting drugs...
12 February 2016 | By Victoria White
The CMA has fined a number of pharmaceutical companies for anti-competitive conduct and agreements in relation to the supply of paroxetine...
12 February 2016 | By Victoria White
The recent FDA approval of Adzenys will provide patients who have problems swallowing pills with easy-to-administer drug options, according to GlobalData analyst...
Vitamin D3 (cholecalciferol) is essential for the human body. Low levels of vitamin D3 increase the risk of illness from a range of disorders. Babies, young children, pregnant mothers and old people are at a higher risk.
12 February 2016 | By Victoria White
Kyprolis (carfilzomib) is the first licensed irreversible proteasome inhibitor for use in combination treatment of patients with relapsed multiple myeloma...
12 February 2016 | By Victoria White
Infliximab is a tumour necrosis factor alpha (TNF-alpha) inhibitor used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis...
11 February 2016 | By Quotient Clinical
Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has completed its 100th RapidFACT (Rapid Formulation development And Clinical Testing) program – a significant milestone in the growth of this service, which addresses drug R&D productivity issues...
11 February 2016 | By Victoria White
Incyte has decided to discontinue the Phase 3 JANUS 1 study of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of patients with advanced or metastatic pancreatic cancer.
11 February 2016 | By Victoria White
Results from Ablynx’s worldwide Phase II TITAN study with caplacizumab for patients with acquired thrombotic thrombocytopenic purpura (aTTP) have been published...
11 February 2016 | By Victoria White
Eisai's Halaven (eribulin) is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action...
11 February 2016 | By Victoria White
GBI Research says the impressive growth in the treatment market will be primarily driven by increased disease prevalence during the forecast period...
Source BioScience, the international Laboratory Services and Products business, has launched a revolutionary -70°C walk-in chamber, the Polar50™. The launch event was held at the Company’s flagship facility in Rochdale, UK and included a captivating presentation by the world’s greatest living explorer, Sir Ranulph Fiennes, who has led numerous expeditions…
10 February 2016 | By Victoria White
The study showed that patients with NSCLC lived significantly longer without disease worsening when treated with Alecensa compared to crizotinib...
10 February 2016 | By Victoria White
The Breakthrough Therapy designation was based on the results of a Phase I/II trial in patients with unresectable, metastatic or recurrent synovial sarcoma...
